The politics of place(ment): Problematising the provision of hepatitis C treatment within opiate substitution clinics

Social Science and Medicine

Volumn 74, Issue 2, 2012, Pages 245-253

  Rance, Jake ^a   Newland, Jamee ^a   Hopwood, Max ^a   Treloar, Carla ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Australia; Foucault; Hepatitis C treatment; Opiate substitution therapy; Social space; Stigma; Treatment identities

Indexed keywords

ACCESSIBILITY; DISEASE CONTROL; DISEASE PREVALENCE; DISEASE TREATMENT; EPIDEMIC; HEALTH GEOGRAPHY; HEALTH SERVICES; HEPATITIS; MARGINALIZATION; PUBLIC HEALTH; SOCIAL EXCLUSION;

ANTIVIRAL THERAPY; ARTICLE; AUSTRALIA; GOVERNMENT; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH PROMOTION; HEALTH SERVICE; HEPATITIS C; HUMAN; INTERVIEW; OPIATE SUBSTITUTION TREATMENT; SOCIAL SUPPORT; SOCIOECONOMICS;

AMBULATORY CARE FACILITIES; ANTIVIRAL AGENTS; AUSTRALIA; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH CARE SURVEYS; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C; HUMANS; INTERFERONS; INTERVIEWS AS TOPIC; MALE; METHADONE; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; POLITICS; PREJUDICE; RIBAVIRIN; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE ABUSE, INTRAVENOUS;

AUSTRALIA;

HEPATITIS C VIRUS;

EID: 84855916365     PISSN: 02779536     EISSN: 18735347     Source Type: Journal    
DOI: 10.1016/j.socscimed.2011.10.003     Document Type: Article

References (60)

1. Astone J., Strauss S., Hagan H., Des Jarlais D.C. Outpatient drug treatment program directors' hepatitis C-related beliefs and their relationship to the provision of HCV services. American Journal of Drug & Alcohol Abuse 2004, 30(4):783-797.
2. Australian Institute of Health and Welfare National Opioid Pharmacotherapy Statistics Annual Data (NOPSAD) 2010 collection: Data guide. Cat. no. WP 64 2010, Viewed 13 July 2011, AIHW, Canberra. http://www.aihw.gov.au/publication-detail/%3Fid%3D6442468366.
3. Bourgois P. Disciplining addictions: the bio-politics of methadone and heroin in the United States. Culture Medicine and Psychiatry 2000, 24:165-195.
4. Connell R., Fawcett B., Meagher G. Neoliberalism, new public management and the human service professions. Journal of Sociology 2009, 45(4):331-338.
5. Cornberg M., Wedemyer H., Manns M. Treatment of chronic hepatitis C with pegylated interferon and ribavirin [Review]. Current Gastroenterology Reports 2002, 4:23-30.
6. Cresswell T. The crucial 'where' of graffiti: a geographical analysis of reactions to graffiti in New York. Environment and Planning D: Society and Space 1992, 10(3):329-344.
7. Day C., Haber P. Managing drug dependence in people with hepatitis C. Hepatitis C clinical management in opiate pharmacotherapy settings 2009, 35-42. Australasian Society for HIV Medicine, Sydney. G. Dore, M. Jauncey (Eds.).
8. Doab A., Treloar C., Dore G. Hepatitis C treatment knowledge, attitudes and barriers among current injecting drug users in Australia. Clinical Infectious Diseases 2005, 40(S5):S313-S320.
9. Dore G., Jauncey M. An overview of hepatitis C clinical management in opiate pharmacoptherapy settings. Hepatitis C clinical management in opiate pharmacotherapy settings 2009, 7-14. Australasian Society for HIV Medicine, Sydney. G. Dore, M. Jauncey (Eds.).
10. Eribon D. Insult and the making of the gay self 2004, Duke University Press, Durham and London.
11. Foucault M. Discipline and punish: The birth of the prison 1979, Vintage Books, New York.
12. Foucault M. Power/knowledge: Selected interviews and other writings, 1972-1977 1980, Pantheon, New York. C. Gordon (Ed.).
13. Foucault The subject and power. Critical Inquiry 1982, 8(4):777-795.
14. Foucault M. The Foucault reader 1991, Penguin, London. P. Rabinow (Ed.).
15. Fraser S. The chronotope of the queue: methadone maintenance treatment and the production of time, space and subjects. International Journal of Drug Policy 2006, 17:192-202.
16. Fraser S., Valentine k Substance and substitution: Methadone subjects in liberal societies 2008, Palgrave Macmillan, Basingstoke.
17. Fricker M. Epistemic injustice: Power and the ethics of knowing 2007, Oxford University Press, Oxford.
18. Fried M.W. Side effects of therapy of hepatitis C and their management. Hepatology 2002, 36(Suppl. 1):S237-S244.
19. Goffman E. Stigma: Notes on the management of spoiled identity 1968, Penguin, Harmondsworth.
20. Grebely J., Bryant J., Hull P., Hopwood M., Lavis Y., Dore G.J., et al. Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia. Journal of Viral Hepatitis 2011, 18(4):104-116.
21. Grebely J., Genoway K., Raffa J., Dhadwal G., Rajan T., Showler G., et al. Barriers associated with treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Dependence 2008, 93(1):141-147.
22. Grebely J., Raffa J., Lai C., Krajden M., Fischer B., Kerr T., et al. Low uptake of treatment for hepatitis C virus (HCV) infection in a large community-based cohort of illicit drug users in Vancouver. Hepatology 2007, 46:296A.
23. Hall S. The west and the rest: discourse and power. Formations of modernity 1992, 275-331. Polity Press, Cambridge. S. Hall, B. Gieben (Eds.).
24. Hellard M., Sacks-Davis R., Gold J. Hepatitis C treatment for injecting drug users: a review of the available evidence. Clinical Infectious Diseases 2009, 49:561-573.
25. Hirst P.Q. Power/knowledge - Constructed space and the subject. Grasping the world: The idea of the museum 2004, 380-400. Ashgate Publishing, Aldershot. D. Preziosi, C. Farago (Eds.).
26. Hopwood M., Treloar C. The drugs that dare not speak their name: injecting and other illicit drug use during treatment for hepatitis C infection. International Journal of Drug Policy 2007, 18:374-380.
27. Hopwood M., Treloar C. Resilient coping: applying adaptive responses to prior adversity during treatment for hepatitis C infection. Journal of Health Psychology 2008, 13:17-27.
28. Keane H. Foucault on methadone: beyond biopower. International Journal of Drug Policy 2009, 20:450-452.
29. Lilly R., Quirk A., Rhodes T., Stimson G.V. Sociality in methadone treatment: understanding methadone treatment and service delivery as a social process. Drugs: Education, Prevention and Policy 2000, 7(2):163-178.
30. Litwin A., Kunins H., Berg K., Federman A., Heavner K., Gourevitch M., et al. Hepatitis C management by addiction medicine physicians: results from a national survey. Journal of Substance Abuse Treatment 2007, 33:99-106.
31. Majer M., Welberg L.A., Capuron L., Pagnoni G., Raison C.L., Miller A.H. IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C. Brain, Behavior and Immunity 2008, 22:870-880.
32. McHoul A., Grace W. Afoucault primer: Discourse, power and the subject 1993, Melbourne University Press, Melbourne.
33. McNally S., Temple-Smith M., Sievert W., Pitts M. Now, later or never? Challenges associated with hepatitis C treatment. Australian and New Zealand Journal of Public Health 2006, 30(5):422-427.
34. Mehta S., Genberg B.L., Astemborsk J., Kavasery R., Kirk G.D., Vlahov D., et al. Limited uptake of hepatitis C treatment among injection drug users. Journal of Community Health 2008, 33:126-133.
35. Miller P.G. Acriticical review of the harm minimization ideology in Australia. Critical Public Health 2001, 11(2):167-178.
36. Mugford S. Social change and the control of psychotropic drugs: risk management, harm reductin and 'postmodernity'. Drug and Alcohol Review 1993, 12:369-375.
37. Norman J., Walsh N., Mugavin J., Stoove M.A., Kelsall J., Austin K., et al. Apeer and community-based model of HCV treatment delivery to injecting drug users: an evaluation of patient perspectives. Hepatitis C clinical management in opiate pharmacotherapy settings 2009, 92-98. Australasian Society for HIV Medicine, Sydney. G. Dore, M. Jauncey (Eds.).
38. Novick D., Kreek M.J. Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction 2008, 103(6):905-918.
39. Parker R., Aggleton P. HIV and AIDS-related stigma and discrimination: a conceptual framework and implications for action. Social Science & Medicine 2003, 57(1):13-24.
40. Paterson B.L., Backmund M., Hirsch G., Yim C. The depiction of stigmatization in research about hepatitis C. International Journal of Drug Policy 2007, 18(5):364-373.
41. Potgieter, Z., Hickey, B., Matthews, G., & Dore, G. (2005). Hepatitis C treatment discontinuation and response: Improved management of morbidity. Paper presented at the 17th Annual Conference of the Australasian Society for HIV Medicine.
42. Radcliffe P., Stevens A. Are drug treatment services only for 'thieving junkie scumbags'? Drug users and the management of stigmatised identities. Social Science & Medicine 2008, 67(7):1065-1073.
43. Ramazanoglu C. Introduction. Up against Foucault: Explorations of some tensions between Foucault and feminism 1993, 1-24. Routledge, London. C. Ramazanoglu (Ed.).
44. Rance J., Fraser S. Accidental intimacy: emotional transformation and the Sydney Medically Supervised Injecting Centre. Contemporary Drug Problems 2011, 38(Spring):121-145.
45. Smith C.B.R. Socio-spatial stigmatization and the contested space of addiction treatment: remapping strategies of opposition to the disorder of drugs. Social Science & Medicine 2010, 70(6):859-866.
46. Smith C.B.R. 'A users' guide to "juice bars" and "liquid handcuffs": fluid negotiations of subjectivity, space and the substance of methadone treatment. Space and Culture 2011, 14(3):291-309.
47. Soja E. Postmodern geographies: The reasssertion of space in critical social theory 1989, Verso, London.
48. Sylvestre D. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug and Alcohol Dependence 2002, 67:117-123.
49. Sylvestre D., Litwin A., Clements B., Gourevitch M. The impact of hepatitis C virus treatment in recovering heroin users maintained on methadone. Journal of Substance Abuse Treatment 2005, 29:159-165.
50. Sylvestre D., Zweben J. Integrating HCV services for drug users: a model to improve engagement and outcomes. International Journal of Drug Policy 2007, 18(5):406-410.
51. Takahashi L.M. The socio-spatial stigmatization of homelessness and HIV/AIDS: toward an explanation of the NIMBY syndrome. Social Science & Medicine 1997, 45(6):903-914.
52. Treloar C., Hull P., Bryant J., Hopwood M., Grebely J., Lavis Y. Factors associated with hepatitis C knowledge among a sample of treatment naive people who inject drugs. Drug and Alcohol Dependence 2011, 116(1-3):52-56.
53. Treloar C., Fraser S. Hepatitis C treatment: increasing treatment uptake needs a critical view [Commentary]. Drug and Alcohol Review 2009, 28:436-440.
54. Treloar C., Fraser S., Valentine k Valuing methadone take-away doses: the contribution of service user perspectives to policy and practice. Drugs: Education, Prevention & Policy 2007, 14(1):61-74.
55. Treloar C., Newland J., Rance J., Hopwood M. Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals. Journal of Viral Hepatitis 2010, 17:839-844.
56. Turner B. The new medical sociology: Social forms of health and illness 2004, W.W. Norton & Company, New York.
57. Twigg J. The body in health and social care 2006, Palgrave Macmillan, Basingstoke.
58. Ward J., Mattick R., Hall W. Methadone maintenance treatment and other opioid replacement therapies 1998, Harwood Academic Publishers, Amsterdam.
59. Winstock A., Anderson C., Sheridan J. National survey of HIV and hepatitis testing and vaccination services provided by drug and alcohol agencies in Australia. Medical Journal of Australia 2006, 184(11):560-562.
60. Wright G., Rabinow P. Spatialisation of power: a discussion of the work of Michel Foucualt. Skyline 1992, 14-20.